Medpace Holdings Reports Strong Q1 2025 Results

Medpace Holdings Inc ( (MEDP) ) has released its Q1 earnings. Here is a breakdown of the information Medpace Holdings Inc presented to its investors.

Medpace Holdings, Inc. is a global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Headquartered in Cincinnati, Ohio, Medpace is known for its scientifically-driven approach and expertise across various therapeutic areas.

In its first quarter of 2025 earnings report, Medpace Holdings, Inc. announced a revenue increase of 9.3% year-over-year, reaching $558.6 million. Despite the revenue growth, the company experienced a decline in net new business awards, which fell by 18.8% compared to the previous year.

Key financial metrics for the first quarter of 2025 include a GAAP net income of $114.6 million, or $3.67 per diluted share, reflecting an increase from the prior year’s $102.6 million, or $3.20 per diluted share. The company’s EBITDA rose by 2.6% to $118.6 million, maintaining a strong EBITDA margin of 21.2%. Additionally, Medpace repurchased shares worth $389.8 million and announced an increase of $1.0 billion to its stock repurchase program.

Looking ahead, Medpace forecasts its 2025 revenue to range between $2.140 billion and $2.240 billion, with GAAP net income expected to be between $378.0 million and $402.0 million. The company remains focused on leveraging its expertise to drive growth and maintain its competitive position in the clinical research industry.